The frontline combination of camrelizumab and chemotherapy resulted in improved overall survival and progression-free survival and a manageable safety profile compared with placebo plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.
The overall survival benefit of immunotherapy combinations compared with sunitinib for the treatment of patients with metastatic renal cell carcinoma who have favorable risk may differ from those who have intermediate or poor risk, according to a pooled analysis of frontline combination therapy conducted by the FDA.
Neeraj Agarwal, MD, discusses the health-related quality of life and patient-reported outcomes in the TITAN trial of apalutamide versus placebo patients with metastatic castration-sensitive prostate cancer.
Improved survival outcomes were reported with the addition of nivolumab to either ipilimumab or chemo-therapy vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or meta-static esophageal squamous cell carcinoma.
Treatment for a patient with chronic lymphocytic leukemia who has comorbidities including hypertension and atrial fibrillation was the topic of discussion during a Targeted Oncology Case-Based Roundtable event led by Parameswaran Venugopal, MD.
Based on a review of immune checkpoint inhibitor mechanisms of action and clinical trial data, SITC has published a clinical practice guideline, which provides key recommendations for managing immune-related adverse events.
The FDA has approved the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced endometrial cancer that is not microsatellite instability–high or mismatch repair deficient, who have disease progression following prior systemic treatment and who are not candidates for curative surgery or radiation.
Debu Tripathy, MD, discusses the use of tucatinib, capecitabine, and trastuzumab for the treatment of patients with HER2-positive breast cancer and leptomeningeal disease in other HER2-positive cancer types.
In the case that a clinical trial is not an option for a 75-year-old male patient with diffuse large B-cell lymphoma who is ineligible for transplant due to older age and high risk. Herbert A. Eradat, MD, explains his treatment plan.